Metformin | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Metformin
US Patents

PharmaCompass Sponsored Ads

Contact Supplier

Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

Contact Supplier

Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

xyz-pharma-m-2025-01-06

Contact Supplier

Metformin

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

106 API Suppliers, 55 USDMF, 40 CEP/COS, 13 JDMF, 29 EU WC, 96 KDMF, 40 NDC API, 43 Listed Suppliers, $ API Reference Price

106 API Suppliers
55 USDMF
40 CEP/COS
13 JDMF
29 EU WC
96 KDMF
40 NDC API
43 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

26 Drugs in Development

26 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1867 FDF Dossiers, 416 FDA Orange Book, 545 Europe, 131 Canada, 122 Australia, 120 South Africa, 533 Listed Dossiers

1867 FDF Dossiers
416 FDA Orange Book
545 Europe
131 Canada
122 Australia
120 South Africa
533 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE, TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE, TABLET;ORAL - 2.5MG;1GM, TABLET;ORAL - 2.5MG;500MG, TABLET;ORAL - 2.5MG;850MG, TABLET;ORAL - EQ 12.5MG BASE;1GM, TABLET;ORAL - EQ 12.5MG BASE;500MG, TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG, TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG, TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;ORAL - 500MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG, TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE, TABLET;ORAL - 1GM;EQ 50MG BASE, TABLET;ORAL - 500MG;EQ 50MG BASE, TABLET;ORAL - 500MG;1MG, TABLET;ORAL - 500MG;2MG

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE
TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE
TABLET;ORAL - 2.5MG;1GM
TABLET;ORAL - 2.5MG;500MG
TABLET;ORAL - 2.5MG;850MG
TABLET;ORAL - EQ 12.5MG BASE;1GM
TABLET;ORAL - EQ 12.5MG BASE;500MG
TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM
TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG
TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM
TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG
TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML
TABLET, EXTENDED RELEASE;ORAL - 1GM
TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;ORAL - 500MG/5ML
TABLET, EXTENDED RELEASE;ORAL - 1GM
TABLET, EXTENDED RELEASE;ORAL - 500MG
TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 850MG;EQ 15MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE
TABLET;ORAL - 1GM;EQ 50MG BASE
TABLET;ORAL - 500MG;EQ 50MG BASE
TABLET;ORAL - 500MG;1MG
TABLET;ORAL - 500MG;2MG

RELATED EXCIPIENT COMPANIES

2 Minakem, 8 Evonik, 8 Rochem International Inc, 22 SPI Pharma, 2 Seqens, 15 DKSH, 3 Pharm-RX Chemical, 10 Faran Shimi Pharmaceutical, 13 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 16 Gangwal Healthcare, 12 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 ACG Worldwide, 12 Actylis, 3 Aeon Procare, 4 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 38 BASF, 1 Bioplus Life Sciences, 2 Clariant, 27 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 39 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 5 Lubrizol Life Science Health, 22 Microlex e.U, 2 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 5 Novo Excipients, 5 Pharmatrans-Sanaq, 12 Pluviaendo, 6 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 35 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 4 The Dow Chemical Company, 3 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

126 Fillers, Diluents & Binders, 68 Coating Systems & Additives, 62 Direct Compression, 58 Controlled & Modified Release, 50 Disintegrants & Superdisintegrants, 50 Thickeners and Stabilizers, 47 Solubilizers, 42 Film Formers & Plasticizers, 42 Taste Masking, 41 Granulation, 36 Topical, 32 Lubricants & Glidants, 31 Parenteral, 24 Chewable & Orodispersible Aids, 23 Co-Processed Excipients, 15 Emulsifying Agents, 12 API Stability Enhancers, 10 Rheology Modifiers, 6 Surfactant & Foaming Agents, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

126 Fillers, Diluents & Binders
68 Coating Systems & Additives
62 Direct Compression
58 Controlled & Modified Release
50 Disintegrants & Superdisintegrants
50 Thickeners and Stabilizers
47 Solubilizers
42 Film Formers & Plasticizers
42 Taste Masking
41 Granulation
36 Topical
32 Lubricants & Glidants
31 Parenteral
24 Chewable & Orodispersible Aids
23 Co-Processed Excipients
15 Emulsifying Agents
12 API Stability Enhancers
10 Rheology Modifiers
6 Surfactant & Foaming Agents
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

21 DATA COMPILATION #PharmaFlow, 366 NEWS #PharmaBuzz

21 DATA COMPILATION #PharmaFlow
366 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 505 Finished Drug Prices, 25 Annual Reports

3 US Medicaid Prescriptions
505 Finished Drug Prices
25 Annual Reports

MARKET PLACE

81 APIs, 51 FDF Dossiers

81 APIs
51 FDF Dossiers

PATENTS & EXCLUSIVITIES

570 US Patents, 50 US Exclusivities, 17 Health Canada Patents

570 US Patents
50 US Exclusivities
17 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 11 Others

3 EDQM
3 USP
11 Others

ANALYTICAL

2 BioAnalytical Methods, 1 Analytical Methods

2 BioAnalytical Methods
1 Analytical Methods

$ API Ref.Price (USD/KG) : 4 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

570 All

01 100ASTRAZENECA AB

02 334BOEHRINGER INGELHEIM

03 92JANSSEN PHARMS

04 26MSD SUB MERCK

05 1SANTARUS INC

06 1SUN PHARM

07 16TAKEDA PHARMS USA

filter Patent Number Reset all filters

570 All

01 510022379*PED

02 1210258637*PED

03 410596120*PED

04 410610489*PED

05 310973827*PED

06 1211090323*PED

07 96515117

08 57326708

09 97407955

10 127579449

11 127713938

12 17780987

13 27785627

14 27807689

15 97919598

16 247943582

17 87943788

18 27959946

19 48080580

20 28173663

21 248222219

22 28288539

23 28414921

24 98501698

25 248513202

26 48551957

27 78628799

28 58673927

29 58685934

30 48716251

31 910022379

32 1210258637

33 410406172

34 1610596120

35 410610489

36 310973827

37 1211090323

38 311564886

39 411576894

40 411813275

41 2411833166

42 511911388

43 1212115179

44 96515117*PED

45 57326708*PED

46 97407955*PED

47 127579449*PED

48 127713938*PED

49 97919598*PED

50 28414921*PED

51 98501698*PED

52 48551957*PED

53 58673927*PED

54 58685934*PED

55 48716251*PED

56 88785403

57 38846695

58 38846695*PED

59 98883805

60 98883805*PED

61 28900638

62 29101660

63 99155705

64 59155705*PED

65 29173859

66 29173859*PED

67 49308204

68 29320714

69 39339472

70 99415016

71 59415016*PED

72 49439902

73 49555001

74 29555001*PED

75 99616028

76 99616028*PED

77 169949997

78 89949997*PED

79 89949998

80 89949998*PED

81 19962336

filter API Patent Reset all filters

570 All

01 121Y

02 449Blank

filter FDF Patent Reset all filters

570 All

01 230Y

02 340Blank

filter Expiration Date Reset all filters

570 All

01 82024-07-30

02 22025-03-15

03 12025-03-23

04 242025-04-11

05 92025-05-02

06 22025-06-24

07 102025-07-13

08 92025-10-04

09 92025-11-02

10 92025-11-26

11 92026-04-04

12 92026-05-26

13 42026-07-31

14 52026-11-24

15 22027-01-22

16 122027-04-15

17 72027-05-04

18 52027-05-24

19 92027-06-20

20 82027-07-14

21 122027-10-15

22 72027-11-04

23 242027-12-03

24 92027-12-20

25 42028-03-21

26 22028-06-27

27 22028-07-21

28 122028-08-01

29 42028-09-21

30 22029-01-21

31 122029-02-01

32 22029-02-03

33 242029-02-26

34 212029-04-02

35 22029-05-24

36 132029-10-02

37 42029-10-14

38 92029-12-16

39 122030-02-11

40 52030-04-10

41 42030-04-14

42 92030-05-21

43 52030-05-26

44 32030-06-04

45 42030-06-15

46 92030-06-16

47 42030-07-06

48 42030-07-13

49 42030-09-30

50 82030-10-21

51 92030-11-12

52 52030-11-21

53 52030-11-26

54 32030-12-04

55 42031-03-30

56 92031-05-12

57 192032-03-07

58 42032-09-07

59 42033-03-06

60 22033-09-06

61 522034-04-03

62 162034-05-17

63 82034-06-11

64 242034-10-03

65 82034-11-17

66 82034-12-11

67 12035-05-01

Granules Metformin

Product Main Page

01

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-05-26

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8685934

Drug Substance Claim :

Drug Product Claim :

Application Number : 205649

Patent Use Code : U-1522

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2030-05-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

PharmaVenue

Not Confirmed

ASTRAZENECA AB

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?